{"id":29662,"date":"2019-05-17T04:18:13","date_gmt":"2019-05-17T04:18:13","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=29662"},"modified":"2019-05-17T04:18:13","modified_gmt":"2019-05-17T04:18:13","slug":"ticagrelor-vs-other-p2y12-inhibitors","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/","title":{"rendered":"Ticagrelor vs other P2Y12 inhibitors"},"content":{"rendered":"<h1><span style=\"color: #008000;\">Ticagrelor vs other P2Y12 inhibitors<\/span><\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-29666\" src=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2019\/05\/Ticagrelor-vs-other-P2Y12-inhibitors.jpg\" alt=\"\" width=\"880\" height=\"496\" \/><\/p>\n<ol>\n<li>Ticagrelor is a reversible P2Y<sub>12 <\/sub>receptor inhibitor whereas clopidogrel and prasugrel are irreversible inhibitors.<\/li>\n<li>Ticagrelor does not require metabolic activation, absorption is rapid and half life is between 7-12 hours; while clopidogrel and prasugrel requires metabolic activation<\/li>\n<li>P2Y<sub>12 <\/sub>receptor inhibition by ticagrelor is more rapid and achieves a markedly higher degree of inhibition of adenosine diphosphate (ADP) mediated platelet aggregation. This is possibly a reason for higher degree of bleeding with ticagrelor than clopidogrel.<\/li>\n<li>Lower rates of fatal bleeds with ticagrelor compared to prasugrel is thought to be due to the reversible nature of inhibition with ticagrelor compared to the irreversible\u00a0P2Y<sub>12 <\/sub>receptor inhibition by prasugrel.<\/li>\n<\/ol>\n<h2><span style=\"color: #0000ff;\">Reference<\/span><\/h2>\n<ol>\n<li>Arora S, Shemisa K, Vaduganathan M, Qamar A, Gupta A,\u00a0 Garg SK, Kumbhani DJ, Mayo M, Khalili H, Pandey A, Das SR. Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD. J Am Coll Cardiol. 2019;73(19): 2454-64.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Ticagrelor vs other P2Y12 inhibitors Ticagrelor is a reversible P2Y12 receptor inhibitor whereas clopidogrel and prasugrel are irreversible inhibitors. Ticagrelor does not require metabolic activation, absorption is rapid and half life is between 7-12 hours; while clopidogrel and prasugrel requires metabolic activation P2Y12 receptor inhibition by ticagrelor is more rapid and achieves a markedly higher [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":29666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[2],"tags":[],"class_list":["post-29662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ticagrelor vs other P2Y12 inhibitors - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ticagrelor vs other P2Y12 inhibitors - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Ticagrelor vs other P2Y12 inhibitors Ticagrelor is a reversible P2Y12 receptor inhibitor whereas clopidogrel and prasugrel are irreversible inhibitors. Ticagrelor does not require metabolic activation, absorption is rapid and half life is between 7-12 hours; while clopidogrel and prasugrel requires metabolic activation P2Y12 receptor inhibition by ticagrelor is more rapid and achieves a markedly higher [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-17T04:18:13+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Ticagrelor vs other P2Y12 inhibitors\",\"datePublished\":\"2019-05-17T04:18:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/\"},\"wordCount\":158,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/\",\"name\":\"Ticagrelor vs other P2Y12 inhibitors - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2019-05-17T04:18:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ticagrelor-vs-other-p2y12-inhibitors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ticagrelor vs other P2Y12 inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ticagrelor vs other P2Y12 inhibitors - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"Ticagrelor vs other P2Y12 inhibitors - All About Cardiovascular System and Disorders","og_description":"Ticagrelor vs other P2Y12 inhibitors Ticagrelor is a reversible P2Y12 receptor inhibitor whereas clopidogrel and prasugrel are irreversible inhibitors. Ticagrelor does not require metabolic activation, absorption is rapid and half life is between 7-12 hours; while clopidogrel and prasugrel requires metabolic activation P2Y12 receptor inhibition by ticagrelor is more rapid and achieves a markedly higher [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2019-05-17T04:18:13+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Ticagrelor vs other P2Y12 inhibitors","datePublished":"2019-05-17T04:18:13+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/"},"wordCount":158,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/#primaryimage"},"thumbnailUrl":"","articleSection":["Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/","url":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/","name":"Ticagrelor vs other P2Y12 inhibitors - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/#primaryimage"},"thumbnailUrl":"","datePublished":"2019-05-17T04:18:13+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/ticagrelor-vs-other-p2y12-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Ticagrelor vs other P2Y12 inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/29662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=29662"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/29662\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=29662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=29662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=29662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}